real peptides FAQ

Resume dosing at the next scheduled interval. Do not double-dose to compensate for a missed administration. SS-31's effects on mitochondrial function are reversible: cardiolipin stabilization persists only while the peptide remains bound to the membrane. A single missed dose in a chronic protocol will cause a temporary decline in mitochondrial efficiency, but the effect resets once dosing resumes. This differs from cumulative therapies where missing doses creates a deficit that's difficult to recover. The practical takeaway: consistency matters for sustained benefit, but occasional lapses don't negate prior treatment effects.

Refrigeration between 2–8°C does not harm bacteriostatic water and may provide marginal bacterial growth inhibition if contamination has occurred, but it does not extend the 28-day use window or reactivate depleted benzyl alcohol. The 28-day timeline is a regulatory standard based on preservative efficacy under controlled room temperature storage. Refrigeration is neither required nor prohibited. If you prefer refrigerated storage for workflow consistency (keeping BAC water next to reconstituted peptides), continue using it, but discard after 28 days regardless of storage temperature.

Refrigerate reconstituted peptides immediately and avoid repeated temperature excursions. NAD+ in solution hydrolyzes at 2–3% per week at 4°C. That rate doubles at room temperature (20–25°C). A single 2-hour excursion reduces potency by less than 1%, which is negligible. Three excursions over a 10-day cycle accumulate to 5–8% loss, and ten excursions. Leaving the vial out every day. Can degrade potency by 15–20%. The solution remains clear and sterile, but the dose you think you're administering is significantly lower than the labeled concentration.

Reduce the Semax dose by 50% for three consecutive administrations and maintain the same Selank dose. Headaches from Semax typically indicate excessive melanocortin receptor activation or transient vasoconstriction in cerebral blood vessels. Both resolve with lower doses. If headaches persist beyond 72 hours at reduced Semax dose, discontinue Semax entirely and continue Selank alone for one week before reintroducing Semax at the lower dose. This isolates which peptide is responsible and allows receptor activity to stabilize.

Discard the vial immediately. Do not attempt to use it. Peptides are temperature-sensitive biologics; a single 8–12 hour exposure to room temperature (20–25°C) causes partial denaturation of the amino acid structure, rendering the compound ineffective without any visible change in appearance. There is no reliable home method to test potency after a temperature excursion. Research-grade peptide protocols depend on maintaining cold chain integrity from synthesis through administration. This is why Real Peptides ships all peptides with insulated packaging and temperature-monitoring indicators. A compromised vial means restarting with a fresh supply, not risking an entire cycle on a degraded product.

Do not co-administer SS-31 with Humanin or other cardiolipin-targeting compounds in the same injection window. They compete for the same binding sites on the inner mitochondrial membrane, reducing effective occupancy of both peptides. The binding affinity (Kd) for SS-31 is in the low nanomolar range, meaning it will outcompete most other cardiolipin-binding agents, but the result is wasted peptide and suboptimal membrane coverage. If your protocol requires both, administer SS-31 first and wait 6–8 hours before introducing the second peptide. By then, SS-31 has saturated available cardiolipin sites and the second peptide can bind to newly synthesized cardiolipin in nascent mitochondria or work through secondary mechanisms that don't require direct cardiolipin interaction.

SS-31's mechanism targets cardiolipin stabilisation and cristae architecture, which are disrupted across all mitochondrial diseases regardless of the specific genetic lesion. Patients with novel mtDNA mutations. Whether affecting Complex I, III, IV, or tRNA genes. Share the same downstream pathology: cardiolipin oxidation, cristae disorganisation, and impaired ATP synthesis. Preclinical evidence shows elamipretide efficacy in mtDNA mutator mice carrying random mutations across the mitochondrial genome, suggesting the intervention is mutation-agnostic. However, the degree of clinical benefit likely depends on residual respiratory chain capacity. Patients with near-complete loss of Complex IV activity, for example, may experience smaller functional gains than those with partial defects.

Do not use it. Cloudiness or visible particles indicate aggregation or precipitation. Signs that protein structure has been compromised through pH shift, contamination, or improper reconstitution technique. Properly reconstituted VIP should be crystal clear with no visible particles when held against white background under good lighting. Cloudy solutions suggest the bacteriostatic water pH was incorrect (should be 6.5–7.5), the lyophilized powder was exposed to moisture before reconstitution, or the solution was frozen and thawed (which denatures VIP irreversibly). Filter the solution through 0.22 micron filter if you suspect particulate contamination, but if cloudiness persists, the batch is lost.

Reduce dose by 30–50% and extend dosing intervals from 48 hours to 72 hours. Myostatin is expressed in cardiac muscle as well as skeletal muscle, and systemic Follistatin-344 inhibits both. Mild left ventricular wall thickening has been documented in long-duration animal studies using doses above 500 mcg/kg, but these changes are typically reversible within 4–6 weeks of dose reduction or discontinuation. Cardiac hypertrophy risk increases with cumulative dose rather than peak dose, so intermittent dosing protocols (e.g., 4 weeks on, 2 weeks off) may reduce risk while preserving body composition effects. Echocardiography or cardiac MRI should be incorporated into protocols exceeding 12 weeks to monitor ventricular dimensions, and any structural changes exceeding 10% from baseline warrant protocol modification. For laboratories studying body composition without cardiac involvement, co-administration of low-dose beta-blockers has been explored in some models to mitigate cardiac load, though this introduces additional variables.

Longer administration timelines don't bypass diminishing returns. Myostatin suppression effect plateaus as the body reaches a new homeostatic set point within the constraints of training stimulus, caloric intake, and genetic ceiling. Published protocols rarely extend beyond 16 weeks due to cost and the observation that hypertrophy rate slows significantly after week 12 even with continued administration. Extended cycles also increase the probability of antibody formation against exogenous follistatin, which reduces binding efficacy over time. Research designs should include washout periods and measure regression rates during follow-up to isolate peptide-specific effects from training adaptation.

Discard it—cloudiness or visible particulates indicate protein aggregation from degradation, contamination, or synthesis errors that render the peptide biologically inactive. Aggregated follistatin-344 cannot bind to myostatin or activin receptors because the three-dimensional structure required for receptor recognition has collapsed into insoluble clumps. This is not a reconstitution technique error—genuine follistatin-344 dissolves completely within 60 seconds of gentle swirling in bacteriostatic water, forming a crystal-clear solution. Persistent turbidity after five minutes is definitive evidence the peptide has degraded or was synthesized incorrectly.

Administer the dose with a small amount of bland food (crackers, rice) to buffer gastric irritation without significantly affecting absorption. While SS-31 oral bioavailability is marginally higher in fasted states, the difference is approximately 10–15%—far less than the compliance and data quality loss from subjects who develop conditioned nausea responses to dosing. A small carbohydrate snack (15–20 grams) consumed 5 minutes before administration provides gastric buffering and reduces vagal nausea signaling while having minimal impact on peptide pharmacokinetics. Avoid high-fat foods which delay gastric emptying by 45+ minutes and extend acid exposure time.

Use the reconstituted peptide within 24 hours and refrigerate continuously between doses. Sterile water lacks benzyl alcohol preservative, meaning bacterial contamination risk increases with every needle puncture after the initial reconstitution. If you've already drawn multiple doses over several days, discard the vial. The contamination risk outweighs the peptide cost. For single-dose vials where the entire contents are drawn immediately after mixing, sterile water works identically to BAC water since no multi-dose exposure occurs.

Transition from acute cardioprotection to chronic metabolic support by using SS-31 mitochondrial membrane stabilization at lower doses over extended periods. In heart failure, mitochondrial dysfunction is progressive. Cardiolipin content per mitochondrion declines by 30–40% in failing human hearts, cristae density decreases, and ATP synthesis capacity per gram of tissue drops proportionally. A 2016 Phase IIA trial in heart failure patients (LVEF <35%) showed that 4 mg/kg/day SS-31 infusion for 4 hours improved diastolic function within 1 hour, measured by reduced LV end-diastolic pressure and increased dP/dt max. The effect persisted for 3–5 days post-infusion, suggesting that even transient SS-31 mitochondrial membrane stabilization allows endogenous repair mechanisms to stabilize cardiolipin pools. Chronic dosing strategies are under investigation. Weekly or biweekly subcutaneous injections may provide sustained benefit without requiring continuous infusion.

Do not use that BAC water for any research protocol requiring reproducibility or regulatory documentation. A legitimate Certificate of Analysis (CoA) includes the specific lot number, manufacturing date, expiration date, and quantitative test results for sterility (USP <71>), bacterial endotoxins (USP <85> LAL test with EU/mL result), pH measurement, and benzyl alcohol assay by HPLC. Suppliers who refuse to provide CoA documentation, claim it is proprietary, or offer only generic specification sheets without lot-specific test data are not manufacturing under pharmaceutical standards and cannot verify the product meets USP monograph requirements. Research institutions conducting grant-funded studies, clinical trials, or any work subject to regulatory audit must maintain documentation proving all reagents and solvents meet specified quality standards—using BAC water without verifiable CoA creates an audit finding and a protocol deviation that compromises data integrity. The absence of legitimate CoA is the clearest indicator that a product is not pharmaceutical-grade.

Discard the solution immediately and do not use it. Properly reconstituted SS-31 should appear as a clear, colorless to slightly yellow solution. Any cloudiness, precipitation, or visible particles indicates either contamination, improper storage, or peptide aggregation. The most common cause is reconstitution with water that was not sterile or injection technique that introduced particulates from a used needle. Less commonly, cloudiness results from attempting to reconstitute SS-31 that was stored above −20°C for extended periods, causing partial degradation and aggregation of hydrophobic peptide fragments. Never filter cloudy peptide solutions through a syringe filter and assume they're now usable. Filtration removes visible particles but not the degraded peptide species that caused aggregation in the first place.

Severe symptoms suggest one of three preparation errors: reconstitution with benzyl alcohol-containing bacteriostatic water instead of preservative-free saline, contamination during reconstitution introducing bacterial endotoxins, or administration technique directing VIP into sinus cavities rather than nasal mucosa. Discontinue current vial immediately. Headache resolving within 10 minutes after proper administration is normal—VPAC receptor activation in trigeminal nerve distributions causes transient vasodilation. Persistent pain lasting 30+ minutes or escalating in severity indicates inflammatory response, not therapeutic effect. Prepare fresh VIP using sterile technique with preservative-free 0.9% saline, and adjust spray angle to prevent sinus penetration.

A single freeze may reduce potency by 20-40% depending on the peptide's structural complexity. Peptides with disulfide bonds like Thymosin Alpha-1 tolerate freezing slightly better than linear peptides, but all reconstituted peptides suffer ice crystal-induced structural disruption when frozen. If it's a high-value compound and you have no replacement, thaw it slowly at 2-8°C, gently swirl to re-mix, and visually inspect for aggregation. Use it immediately—do not refreeze. If appearance is normal and it's a peptide with a measurable acute effect (like ipamorelin causing GH spike), you may be able to verify partial activity through biomarker testing. If it's a long-timeline peptide like a GLP-1 agonist, you will not know potency loss until weeks into the protocol, at which point your timeline data is compromised. The professional move: discard and reconstitute fresh material. Salvaging frozen peptides introduces unquantifiable error into every subsequent result.

Myostatin inhibition can theoretically impair adipose tissue remodeling in models with pre-existing metabolic dysfunction. Myostatin plays a role in adipocyte differentiation, and complete inhibition may paradoxically reduce fat oxidation capacity. If metabolic markers worsen, reduce follistatin-344 dosing frequency to once weekly rather than twice weekly, allowing partial myostatin activity to resume. Pairing with 5 Amino 1MQ can offset this by enhancing nicotinamide metabolism and mitochondrial function independent of myostatin pathways.

Reduce the administration volume and increase peptide concentration to deliver the same total dose in a smaller volume. Most irritation results from osmotic stress rather than the peptides themselves. If irritation persists, switch to subcutaneous administration or add 0.01% polysorbate 80 to the intranasal solution to improve mucosal tolerance. Some labs alternate nostrils daily to allow recovery time between administrations.